Search hospitals > Maryland > Bethesda

Walter Reed National Military Medical Center

Claim this profile
Bethesda, Maryland 20814
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Breast cancer
Conducts research for Ovarian Cancer
455 reported clinical trials
35 medical researchers
Photo of Walter Reed National Military Medical Center in BethesdaPhoto of Walter Reed National Military Medical Center in BethesdaPhoto of Walter Reed National Military Medical Center in Bethesda

Summary

Walter Reed National Military Medical Center is a medical facility located in Bethesda, Maryland. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Breast cancer, Ovarian Cancer and other specialties. Walter Reed National Military Medical Center is involved with conducting 455 clinical trials across 722 conditions. There are 35 research doctors associated with this hospital, such as Rebecca O. Clark, Allen I. Stering, Jeremy Perkins, and Matthew Miller, MD.

Area of expertise

1Breast Cancer
Global Leader
Walter Reed National Military Medical Center has run 46 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
ER negative
2Cancer
Global Leader
Walter Reed National Military Medical Center has run 35 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage I
KRAS positive

Top PIs

Clinical Trials running at Walter Reed National Military Medical Center

Ovarian Cancer
Lung Cancer
Cancer
Breast Cancer
Breast cancer
Uterine Cancer
Testicular cancer
Lymphoma
Prostate Cancer
Neuroblastoma
Image of trial facility.

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.
Recruiting1 award Phase 217 criteria
Image of trial facility.

Selumetinib + Olaparib

for Ovarian and Endometrial Cancer

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Walter Reed National Military Medical Center?
Where is Walter Reed National Military Medical Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does Walter Reed National Military Medical Center accept?
What awards or recognition has Walter Reed National Military Medical Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security